Dasatinib 140 Mg Once Daily (QD) Demonstrates Equivalent Efficacy and Improved Safety Compared with 70 Mg Twice Daily (BID) in Patients with Chronic Myeloid Leukemia in Blast Phase (CML-BP): 2-Year Data from CA180-035
Author:
Giuseppe Saglio,Hagop M. Kantarjian,Andreas Hochhaus,Yeow Tee Goh,Tamas Masszi,Ricardo Pasquini,Frederic Maloisel,M. Brigid Bradley-Garelik,Chao Zhu,Herve Dombret
Copyright © 2008 American Society of Hematology